On October 5, 2020 Trillium Therapeutics Inc. ("Trillium" or the "Company") (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, reported that it has received Notices of Allowance from the United States Patent and Trademark Office for two patent applications covering the use of SIRPαFc for the treatment of cancer, U.S. Patent Application No. 13/320,629 (the "629 Application", exclusively licensed to Trillium) and U.S. Patent Application No. 15/962,540 (the "540 Application") (Press release, Trillium Therapeutics, OCT 5, 2020, View Source [SID1234568090]). Trillium has two SIRPαFc biologics, TTI-621 and TTI-622, in clinical development. Both therapeutics target CD47, a "don’t eat me" signal that cancer cells use to evade immune destruction.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The ‘629 method of use Application provides coverage for the use of SIRPαFc biologics to treat all CD47+ cancer cells and tumours, including hematologic and solid cancers. Counterparts of this application have already been granted in Japan, Canada and Australia.
The ‘540 Application has claims that cover TTI-622 composition of matter comprising human SIRPα linked to an IgG4 Fc region, as well as claims covering pharmaceutical compositions that contain TTI-622. A composition of matter patent for TTI-621 (SIRPα linked to an IgG1 Fc) has already been granted in the U.S. (US 9,969,789) and other countries.
"Intellectual property remains a top priority for Trillium, and the allowance of these two important patents further strengthens our position in the SIRPαFc CD47 space," said Jan Skvarka, President and Chief Executive Officer of Trillium. "In addition to our specific composition-of-matter claims covering both of our CD47-targeting agents, we have expanded our coverage to embrace the use of the SIRPαFc class of biologics to treat cancer. We are particularly pleased that the method of use patent also covers treatment of solid tumors."